“People and their physicians are eager for medicines that put digital to work to improve their treatments and quality of life,” said David Van Sickle, co-founder, and CEO of Propeller Health. “This partnership with Orion is another significant step toward reducing the burden of chronic respiratory disease for people around the world.”
Orion and Propeller Health have announced a partnership to connect Orion’s Easyhaler line of inhalers for asthma and COPD to Propeller’s digital medicine platform. Propeller and Orion will partner to develop a custom sensor for Easyhaler, which will attach to the inhaler and pair to Propeller’s mobile app to track medication use and provide personal feedback. Development begins in 2019, with clinical trials and commercial roll-out to follow.
This partnership expands Propeller’s presence in Europe, where Orion is the market leader in Finland and covers almost all key European markets. Propeller’s platform currently covers more than 90 percent of inhaled medicines for asthma and COPD on the market.